STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

RGNX REGENXBIO INCORPORATED StockScouter® Report

3

StockScouter® Score

REGENXBIO INCORPORATED, a small cap growth company in the healthcare sector, is expected to slightly underperform the market over the next six months with average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • Short-term relative price momentum exhibits meaningful strength. Postive

 

Concerns

  • The most recent quarterly earnings report was significantly lower than analysts’ consensus forecast. Negative
  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
  • One or more analysts has modestly decreased quarterly earnings estimates for RGNX. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that small cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 60% done.
Progress: 40% done.
Low
High

Core Model Grades

F
D
F
B

Previous Ratings

4
6
2